Get the Stockscreener App
189.60
2.38%
-4.62
After Hours:
189.89
0.29
+0.15%
Insmed Inc stock is traded at $189.60, with a volume of 3.16M.
It is down -2.38% in the last 24 hours and up +31.66% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$194.22
Open:
$194.57
24h Volume:
3.16M
Relative Volume:
1.29
Market Cap:
$40.08B
Revenue:
$447.02M
Net Income/Loss:
$-1.18B
P/E Ratio:
-30.67
EPS:
-6.1812
Net Cash Flow:
$-868.57M
1W Performance:
+18.75%
1M Performance:
+31.66%
6M Performance:
+163.33%
1Y Performance:
+181.81%
1-Day Range:
$187.02
$197.08
1-Week Range:
$160.53
$197.08
52-Week Range:
$60.40
$197.08
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Why Insmed Incorporated is moving todayDay Trade & Community Consensus Trade Alerts - newser.com
Earnings Beat: Insmed Incorporated (NASDAQ:INSM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Can Insmed Incorporated stock deliver surprise earnings beatPortfolio Value Report & Safe Swing Trade Setups - newser.com
What dividend safety score for Insmed Incorporated stock2025 Geopolitical Influence & Low Risk Entry Point Tips - newser.com
Historical volatility pattern of Insmed Incorporated visualizedJuly 2025 Earnings & Safe Swing Trade Setups - newser.com
What machine learning models say about Insmed IncorporatedLayoff News & Real-Time Volume Surge Alerts - newser.com
Insmed Incorporated (NASDAQ:INSM) Q3 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo Maintains Insmed (INSM) Overweight Recommendation - Nasdaq
How Insmed Incorporated stock reacts to Fed rate cutsJuly 2025 Breakouts & Expert-Curated Trade Recommendations - newser.com
Is Insmed Incorporated (IM8N) stock a buy before new product rollout2025 Price Momentum & Reliable Trade Execution Plans - newser.com
Insmed (NASDAQ:INSM) Posts Earnings Results, Misses Estimates By $0.40 EPS - MarketBeat
Goldman Sachs Maintains Insmed (INSM) Buy Recommendation - Nasdaq
Insmed Incorporated (INSM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Wells Fargo Raises Price Target for INSM to $217, Maintains Over - GuruFocus
Insmed (NASDAQ:INSM) Hits New 12-Month HighTime to Buy? - MarketBeat
Goldman Sachs Boosts Insmed (INSM) Price Target to $225 | INSM S - GuruFocus
INSM: UBS Maintains 'Buy', Raises Price Target to $223 | INSM St - GuruFocus
Insmed Shares Likely to Gain From Brinsupri Sales, Untapped Pipeline, UBS Says - MarketScreener
Insmed stock surges as UBS raises price target on Brinsupri launch success - Investing.com Canada
Insmed (INSM) Sees Price Target Raised by RBC Capital to $215 | - GuruFocus
Insmed (INSM) Hits All-Time High as Firm Posts Highly Optimistic Outlook - Insider Monkey
Insmed Q3 2025 slides reveal strong BRINSUPRI debut, ARIKAYCE growth accelerates - Investing.com Australia
Insmed stock hits 52-week high at 170.3 USD By Investing.com - Investing.com Australia
RBC Raises Price Target on Insmed to $215 From $139, Keeps Outperform Rating - MarketScreener
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake - TradingView
Cantor Fitzgerald Comments on Insmed FY2025 Earnings - MarketBeat
UBS Adjusts Insmed Price Target to $223 From $194, Maintains Buy Rating - MarketScreener
Truist Raises Price Target on Insmed to $214 From $139, Keeps Buy Rating - MarketScreener
Insmed: Q3 Earnings Snapshot - Stamford Advocate
Emerald Mutual Fund Advisers Trust Sells 328,407 Shares of Insmed, Inc. $INSM - MarketBeat
Emerald Advisers LLC Decreases Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed Reaches Analyst Target Price - Nasdaq
Insmed, Inc. $INSM Shares Sold by Jennison Associates LLC - MarketBeat
Biotech Stocks Hit 52-Week Highs: MTSR, INSM, ABVX, MAZE Lead October 30 Surge - RTTNews
Is Insmed Incorporated (IM8N) stock among top earnings playsPortfolio Gains Summary & AI Optimized Trading Strategy Guides - newser.com
Insmed Q3 2025 Earnings Call Transcript - MarketBeat
Insmed earnings missed by $0.41, revenue topped estimates - Investing.com Canada
Will Insmed Incorporated (IM8N) stock see valuation expansionEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
Will Insmed Incorporated stock outperform Dow Jones indexJuly 2025 Update & Real-Time Chart Pattern Alerts - newser.com
A Look at Insmed (INSM) Valuation Following EU Brensocatib Milestone and ARIKAYCE Revenue Upgrade - Yahoo Finance
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed stock price target raised to $223 by TD Cowen on strong Brinsupri launch - Investing.com Nigeria
Insmed Inc (INSM) Q3 2025 Earnings Call Highlights: Strong Launch for Brin Suri and Robust ... By GuruFocus - Investing.com Canada
Insmed Incorporated (INSM) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
INSM: On the Rise Again or Just a Bubble? - StocksToTrade
Insmed Inc (INSM) Q3 2025 Earnings Call Highlights: Strong Launch for Brin Suri and Robust ... - Yahoo! Finance UK
Insmed price target raised to $196 from $165 at Mizuho - MSN
Insmed Incorporated Raises Global ARIKAYCE Revenue Guidance for the Full Year 2025 - MarketScreener
Insmed Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Insmed Reports Strong Sales Growth And Raises Guidance For 2025 - Finimize
Insmed’s Promising Future: Are Gains Imminent? - StocksToTrade
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.73%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):